Current status of therapy for chronic myeloid leukemia: A review of drug development

Future Oncology

Volumn 4, Issue 3, 2008, Pages 359-377

  Padmanabhan, Swami ^a   Ravella, Saritha ^a   Curiel, Tyler ^a   Giles, Francis ^b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

CML; Cytogenic remission; Dasatinib; Imatinib; IRIS; Molecular remission

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ALPHA INTERFERON; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DIURETIC AGENT; FLUDARABINE; IMATINIB; INTERFERON; NILOTINIB; ONO 12380; PEGINTERFERON; PHA 739358;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL CLONE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CYTOGENETICS; CYTOPENIA; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEART FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; LEG EDEMA; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG EDEMA; MAXIMUM PLASMA CONCENTRATION; MINIMAL RESIDUAL DISEASE; MOLECULAR MECHANICS; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT MONITORING; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 47249138657     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.3.359     Document Type: Review

References (77)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer. J. Clin. 56(2), 106-130 (2006).
2. O'Brien SG, Guilhot F, Larson RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004, (2003).
3. Peng B, Hayes M, Resta D et al.: Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22(5), 935-942 (2004).
4. Schmidli H, Peng B, Riviere GJ et al.: Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a Phase III study. Br. J. Clin. Pharmacol. 60(1), 35-44 (2005).
5. Talpaz M, Silver RT, Druker BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99(6), 1928-1937 (2002).
6. Sawyers CL, Hochhaus A, Feldman E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 99(10), 3530-3539 (2002).
7. Larson RA, Druker BJ, Guilhot F et al.: Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 429).
8. Kantarjian H, Talpaz M, O'Brien SG et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8), 2873-2878 (2004).
9. Druker BJ, Guilhot F, O'Brien SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J Med. 355(23), 2408-2417 (2006).
10. Cortes J, O'Brien SG, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104(7), 2204-2205 (2004).
11. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk. Res. 28(Suppl. 1), S71-S73 (2004).
12. Ghanima W, Kahrs J, Dahl TG III, Tjonnfjord GD: Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur. J. Haematol. 72(6), 441-443 (2004).
13. Merante S, Orlandi E, Bernasconi P et al.: Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90(7), 979-981 (2005).
14. Kujawski LA, Talpaz M: The role of interferon-α in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18(5-6), 459-471 (2007).
15. Kerkela R, Grazette L, Yacobi R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12(8), 908-916 (2006).
16. Atallah E, Durand J, Kantarjian H et al.: congestive heart failure is a rare event in patients (pts) receiving imatinib therapy. Blood 108 (11) (2006) (ASH Annual Meeting Abstracts: 2146).
17. Radich JP, Oehler V: Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J. Natl Compr. Canc. Netw. 5(5), 497-504 (2007).
18. Branford S, Cross NC, Hochhaus A et al.: Rationale for the recommendations for harmonizing current methodology for Detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20(11), 1925-1930 (2003).
19. Branford S, Cross NC, Hochhaus A et al.: First results from a collaborative initiative to develop an international scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 737).
20. Kantarjian H, Schiffer C, Jones D, Cortes J: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111, 1774-1780 (2008).
21. Fabarius A, Giehl M, Frank O et al.: Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19(9), 1573-1578 (2005).
22. Bumm T, Muller C, Al-Ali HK et al.: Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101(5), 1941-1949 (2003).
23. Berman E, Nicolaides M, Make RG et al.: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 354(19), 2006-2013 (2006).
24. Kantarjian HM, Rarson RA, Guilhot F, O'Brien SG, Druker BJ; on Behalf of IRIS Study Group: Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the international randomized study of interferon vs STI571 (IRIS). Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 2136).
25. Copland M, Richmond L, Hamilton A et al.: BMS-214662 eliminates CML stem cells and is active against blast crisis CML and cells expressing BCR-ABL kinase mutations. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 739).
26. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004).
27. O'Hare T, Walters DK, Stoffregen EP et al.: Combined Ab1 inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/ Ab1 inhibitors are compatible with imatinib. Clin. Cancer Res. 11(19 Pt 1), 6987-6993 (2005).
28. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl Acad. Sci. USA 102(9), 3395-3400 (2005).
29. Talpaz M, Shah NP, Kantarjian HM et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354(24), 2531-2541 (2006).
30. Hochhaus A, Kantarjian HM, Baccarani M et al.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronit myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007).
31. Guilhot F, Apperley J, Kim DW et al.: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109(10), 4143-4150 (2007).
32. Cortes J, Rousselot P, Kim DW et al.: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109(8), 3207-3213 (2007).
33. Kantarjian HM, Pasquini R, Hamerschlak N et al.: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12), 5143-5150 (2007).
34. Martinelli G, Hochhaus A, Coutre S et al.: Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i). Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 745).
35. +) ALL who are resistant or intolerant to imatinib (im): results of the CA180-035 study. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 746).
36. Brave M, Goodman V, Kaminskas E et al.: Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14(2), 352-359 (2008).
37. Müller MC, Erben P, Schenk T et al.: Response to Dasatinib after imatinib failure according to type of preexisting BCR-ABL mutations. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 748).
38. Ottmann O, Dombret H, Martinelli G et al.: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110(7), 2309-2315 (2007).
39. Cortes J, Kim DW, Guilhod F et al.: Dasatinib (SPRYCEL®) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 'START-A' Phase II Study. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 2160).
40. Dombret H, Ottman O, Rosti G et al.: Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): updated results-from the CA180-015 START-L Study. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 286).
41. Baccarani M, Kantarjian HM, Apperley JF et al.: Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C Phase II study. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 164).
42. Quintas-Cardama A, Kantarjian HM, Munden R et al.: Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 2164).
43. Shah NP, Kim DW, Kantarjian HM et al.: Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J. Clin. Oncol. 25, (Suppl.) 18S (2007) (ASCO Annual Meeting Proceedings: 7004).
44. Weisberg E, Manley P, Mestan J et al.: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94(12), 1765-1769 (2006).
45. O'Hare T, Walters DK, Stoffregen EP et al.: in vitro activity of Bcr-Ab1 inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Ab1 kinase domain mutants. Cancer Res. 65(11), 4500-4505 (2005).
46. Kantarjian HM, Giles F, Wunderle, L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542-2551 (2006).
47. Kantarjian HM, Giles F, Gattermann N et al.: Nilotinib (formerly AMN107), a highly selective Bcr-Ab1 tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 110(10), 3540-3546 (2007).
48. Ottmann O, Kantarjian HM, Larson R et al.: A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 1862).
49. Le Coutre P, Ottmann OG, Giles F et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834-1839 (2008).
50. Lombardo LJ, Lee FY, Chen P et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Ab1 kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47(27), 6658-6661 (2004).
51. Schittenhelm MM, Shiraga S, Schroeder A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66(1), 473-481 (2006).
52. Kathula SK: Dasatinib in chronic myelogenous leukemia. N. Engl. J. Med. 355(10), 1062; author reply 1063-1064 (2006).
53. Golas JM, Arndt K, Etienne C et al.: SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Ab1 kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63(2), 375-381 (2003).
54. Cortes J, Kantarjian HM, Baccarani M et al.: A Phase 1/2 study of ski-606, a dual inhibitor of Src and Ab1 kinases, in adult patients with philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 108(11) (2006) (ASH Annual Meeting Abstracts: 168).
55. Kimura S, Naito H, Segawa H et al.: NS-187, a potent and selective dual Bcr-Ab1/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106(12), 3948-3954 (2005).
56. O'Hare T, Pollock R, Stoffregen EP et al.: Inhibition of wild-type and mutant Bcr-Ab1 by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104(8), 2532-2539 (2004).
57. Singer JB, Shou Y, Giles F et al.: UCT1A1 promoter polymorphism, increases risk of nilotinib-induced hyperbilirubinemia. Leukemia (2007) (Epub ahead of print).
58. + neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006).
59. Giet R, Prigent C: Aurora/Ip11p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J. Cell. Sci. 112(Pt 21), 3591-3601 (1999).
60. Harrington EA, Bebbington D, Moore J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10(3), 262-267 (2004).
61. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian HM, Freedman SJ: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109(2), 500-502 (2007).
62. Fancelli D, Moll J, Verasi M et al.: 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49(24), 7247-7251 (2006).
63. Gumireddy K, Baker SJ, Cosenza SC et al.: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib, resistance. Proc. Natl Acad. Sci. USA 102(6), 1992-1997 (2005).
64. Redich JP, Gooley T, Bensinger W et al.: HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102(1), 31-35 (2003).
65. Gratwohl A, Brand R, Apperley J et al.: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91(4), 513-521 (2006).
66. Silver RT, Woolf SH, Hehlmann R et al.: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5), 1517-1536 (1999).
67. Simonsson B, Oberg G, Bjoreman M et al.: Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta. Haematol. 113(3), 155-162 (2005).
68. Robin M, Guardiola P, Deverie A et al.: A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19(9), 1613-1620 (2005).
69. Gratwohi A, Hermans J, Goldman JM et al.: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352(9134), 1087-1092 (1998).
70. Guglielmi C, Arcese W, Dazzi F et al.: Donor lymphocyte Infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100(2), 397-405 (2002).
71. Raiola AM, van Lint MT, Valbonesi M et al.: Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 31 (8), 687-693 (2003).
72. Kolb HJ, Schattenberg A, Goldman JM et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood86(5), 2041-2050 (1995).
73. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ: A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91(5), 663-666 (2006).
74. Kebriaei P, Detry MA, Giralt S: Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110(9), 3456-3462 (2007).
75. Deininger M, Schleuning M, Greinix H et al.: The effect of prior exposure to imatinit, on transplant-related mortality. Haematologica 91(4), 452-459 (2006).
76. Jabbour E, Cortes J, Kantarjian HM et al.: Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2), 340-344 (2007).
77. Jorgensen HG, Allen EK, Gramm SM et al.: Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19(7), 1184-1191 (2005).